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1. Introduction 
The anthiphospholipid syndrome (APS) is characterized by a high risk of venous and 
arterial thrombosis and by complications during pregnancy, especially recurrent 
miscarriages. The thrombotic event is caused by a complex interaction between 
antiphospholipid antibodies (aPLs) and endothelium and platelets. Inflammation may play 
a role in the pathology of APS even though the consensus of Sydney (Miyakis et al., 2006) 
requires the absence of vascular inflammation signs for the diagnosis of APS. However, the 
complement system has recently been involved in the pathogenesis of fetal losses in animal 
models and, interestingly, the protective role of heparin in such cases could be due to the 
complement inhibition rather than to anticoagulation. The treatment of APS is based on 
antiplatelet drugs (aspirin) and anticoagulants (both heparins and vitamin K antagonists). In 
the acute phase the treatment is in general very similar to that of non-APS thrombosis, that 
is with unfractionated heparin (UFH) therapy followed by oral anticoagulation. However, 
APS treatment remains problematic due to lack of standardized laboratory tests and of 
randomized controlled trials (RCTs).  
2. Prophilaxis of thromboembolism 
2.1 Secondary prophylaxis of vascular thrombosis 
The risk of thrombotic recurrences is lower if the venous district, rather than the arterial one, 
is involved. The key issue in the antithrombotic management of APS patients concerns 
whether arterial and venous events should receive the same  intensity of therapy. According 
to Ruiz-Irastorza  review  we can treat lower-risk patients with conventional anticoagulation 
in order to reach Target International Ratio (INR) values between 2.0 and 3.0, reserving 
high-intensity anticoagulation (INR > 3.0) to patients with arterial thrombosis or venous 
thrombotic recurrences (Ruiz-Irastorza et al., 2007). On the contrary Lim argues in his 
systematic review that high-intensity anticoagulation (INR: 3.0-4.0) is not better than 
conventional anticoagulation in protecting patients with first thrombotic venous event and 
non-cerebral arterial thrombosis (Lim et al., 2006). The conclusions are based on two RCTs 
(Crowther et al.,2003; Finazzi et al.,2005) that are susceptible to criticism as: 1. recruitment 
mainly concerns venous thromboses, with the exception of strokes and recurrent 
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thrombosis, the sample is not representative of the APS population. 2. In the high-intensity 
anticoagulation arms, the warfarin dose is often subtherapeutic with frequent thrombotic 
recurrences with INR < 3.0. Cerebral thromboses are the most frequent arterial events of 
APS. The risk of new cerebral thromboses is addressed by the prospective Antiphospholipid 
Antibodies  and Stroke Study (APASS) (Levine et al., 2006), that showed no difference in the 
comparison between a single antiplatelet (aspirin 325 mg/day) and a single anticoagulant 
(warfarin: INR  1.4 - 2.8). In this study the extension of the results to the APS population is 
questionable, as the analysis of aPLs is made on a single sample at the time of enrolment, 
while for the diagnosis of APS it is essential to have at least two measurements taken at a 
distance of some time. A recent small Japanese RCT (Okuma et al., 2009), that instead only 
enrolled patients with definite diagnosis of APS according to the consensus of Sydney, 
shows that the combination of conventional anticoagulation plus low-dose aspirin (LDA) 
(100 mg/day) is more effective than aspirin used on its own. In conclusion, we believe that 
the prevention of arterial thromboses requires either anticoagulation at INR 3.0-4.0 or a 
combined treatment. Apart from the debate  regarding the intensity of anticoagulation, there 
is a general agreement upon it being maintained indefinitely, even if some authors argue 
that a finite treatment can be performed if the first episode of venous thromboembolism 
occurs in the context of a transient and reversible risk factor (surgery, prolonged 
immobilization, pregnancy, estrogen therapy) (Giannakopoulos & Krillis, 2009). 
2.1.1 Prophylaxis of APS obstetric complications 
The pregnancy morbidity of APS includes maternal thromboses, spontaneous abortions 
before the 10th week and late obstetric complications (fetal deaths, premature births caused 
by preeclampsia or placental insufficiency). Pregnant women with aPLs positivity should be 
stratified in order to perform the optimal treatment: A. Women with ascertained APS and 
previous thrombosis, B. Pregnant women with a history of recurrent miscarriages, C. 
Pregnant women with a history of fetal deaths > 10 weeks and premature births <34 weeks. 
A. Women with ascertained APS and previous thrombotic event, possibly already on 
warfarin therapy, should undergo combination therapy with LDA (75-100mg/day) plus 
therapeutic doses of unfractionated heparin (UFH) (subcutaneously every 8-12 h) or low 
molecular weight heparin (LMWH) (e.g. enoxaparin 1 mg/kg subcutaneously every 12 h). 
During pregnancy, warfarin must be stopped between the 6th and the 12th week due to its 
teratogenicity, and also afterwards it can cause fetal hemorrhage. B. Women with a history 
of recurrent miscarriages should be  treated with a combination therapy of LDA plus 
prophylactic doses of UFH (5000-7500 IU subcutaneously every 12 h) or LMWH in 
prophylactic doses (e.g., enoxaparin 1 mg/kg/day). C. Women with a history of fetal deaths 
>10 weeks and premature births <34 weeks should be  treated with a combination therapy 
of LDA plus prophylactic/intermediate doses of UFH (e.g., 7500-10000 IU subcutaneously 
every 12 h) or LDA plus LMWH usually in prophylactic doses (e.g., enoxaparin 1 mg/kg 
every 24 hours). These treatment patterns derive from meta-analysis and expert guidelines 
(Empson et al., 2005; Bates et al.,2008) . There is not indisputable evidence that 
anticoagulation with heparins works better than aspirin alone  and  it has not even been 
established which is more effective between UFH or LMWH. In fact, if on the one hand  
RCTs have shown a reduction in the number of pregnancy losses with a combination of 
UFH-LDA, on the other hand  other RCTs, that used LMWH-LDA, do not show a clear 
superiority. There are many observational studies in favor of the effectiveness of LDA alone. 
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Moreover, the PARIS Collaborative Group meta-analysis (Askie et al.,2007) shows that  the 
pregnancy outcome in women at high risk of preeclampsia treated with LDA, is similar to 
that of the general population, after 20 weeks of gestation. Two pilot studies show no 
differences when comparing the LDA-UFH to the LDA-LMWH combination therapy (Noble 
et al., 2005; Stephenson et al., 2004). In order to clarify controversies, a trial with three arms 
is strongly needed: 1. UFH versus LDA, 2. LMWH versus LDA, 3. LDA alone (Mehdi et 
al.,2010)  
2.1.2 Primary prophylaxis of vascular thrombosis 
The group of subjects with aPLs positivity in absence of clinical APS manifestations (aPLs  
carriers), includes asymptomatic carriers, patients with SLE, and pregnant women aPL- 
positive  without  a history of obstetric complications and/or thrombosis. Only some of the 
aPLs carriers will progress towards overt APS and we still do not know why some will 
develop the thrombotic event and others will not. The role played by additional risk factors, 
both congenital and acquired, is also under investigation. It is clear, however, that  the 
elimination of reversible risk factors and the prophylaxis during high risk periods, such as 
prolonged immobilization and surgery, are paramount in the primary prophylaxis of  
thrombosis. In asymptomatic carriers, for whom the risk of thrombosis is very low (<1%), a 
prophylactic use of aspirin is not justified. In the APLASA RCT (Erkan et al., 2007), aspirin 
at 81 mg/day did not prove superior to placebo in preventing the first thrombotic event in 
asymptomatic individuals persistently aPL-positive. Thus, the approach based on 
thrombotic risk stratification is reasonable in healthy carriers, reserving the LDA 
prophylaxis to individuals with additional risk factors (hypertension, diabetes, 
hypercholesterolemia, smoking, estrogen therapy) and/or immunological high risk profile 
(high aPLs titre, especially lupus anticoagulant (LA) and ‘multiple’ positivity: aCL, LA, 
ǃ2GPI). The risk of thrombosis in both SLE patients and  pregnant women carriers, is on the 
other hand higher (3-4% and 3-7% respectively). These categories will benefit from LDA 
prophylaxis as demonstrated by several observational studies (Hereng et al., 2008 ; Erkan et 
al.,2001) . No randomized studies show that hydroxychloroquine, a drug that  reduces 
platelet activation aPL-induced, has also an added prophylactic value in SLE patients 
(Kaiser et al., 2009).  
3. Management of cardiac diseases in APS 
3.1 Introduction 
APL antibodies are associated with a wide spectrum of cardiac manifestations that include 
accelerated atherosclerosis, ischemic coronary artery disease (CAD), valve abnormalities, 
intracardiac thrombosis, pulmonary hypertension (PH). 
3.1.1 Atherosclerosis and APS 
Ischemic coronary artery disease in APS is largely due to atherosclerosis. The fact that the 
population of APS patients does not show an increased prevalence of Framingham 
‘traditional’ risk factors when compared to the general population suggests that other ‘non-
traditional’ risk factors, such as aPLs, might facilitate the development of atherosclerosis.  
Carotid intimal-medial thickness (IMT) detected by B-mode ultrasounds, is a known 
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predictor of coronary artery disease and stroke in adults. An increased frequency of higher 
IMT in patients with APS indicates that they are more likely to incur in atherosclerotic 
events. Ames (Ames et al., 2002) found that anticardiolipin antibodies (aCLs) independently 
predict the extension of IMT in the carotid arteries, while other authors 
(Vlachoyiannopoulos et al., 2003) failed to demonstrate such predictive role of aCLs. Ankle-
brachial pressure index (ABPI), another marker of atherosclerotic risk, is abnormally high in 
APS, but no correlation with aPLs has been found (Baron et al., 2005). In conclusion, it is 
commonly acknowledged that a correlation between aPLs and atherosclerosis exists. APLs 
may play a role in atherogenesis due to procoagulant and proinflammatory effects on 
endothelial cells and/or their interference on LDL and HDL metabolism. 
3.2 Management of coronary artery disease 
The correlation between APS and coronary artery disease (CAD) is not well established. 
Vaarala’s prospective study  on a cohort of 4081 healthy middle-aged men found that a high 
level of aCLs constituted an independent risk factor with relation to myocardial infarction 
(MI) or cardiac death, with high prevalence in patients younger than 45 (22%) (Vaarala et al., 
1995). It is therefore useful to recommend aPLs screening to infarcted  patients under 45 in 
the absence of obvious risk factors. In previous studies the association between aPLs and MI 
has not been demonstrated. Anticoagulation with warfarin is usually prescribed to patients 
who have experienced coronary thrombotic occlusion. Petri in the Hopkins Lupus cohort 
highlighted the protective role of hydroxychloroquine due to the reduction of the lupus 
disease activity, the antiplatelet effect, the reduction of aPLs, and the lipid-lowering effect 
(Petri, 2000). Moreover, high homocysteine levels may be involved in APS-related 
thrombosis, suggesting a potential role of folic acid. Obviously, we need to identify and treat 
traditional cardiovascular risk factors in APS patients, including hypercholesterolemia with 
use of HMG-CoA inhibitors, cholesterol-lowering agents with anti-inflammatory properties. 
In conclusion, the Consensus Committee for treatment of cardiac diseases in APS (Lockshin 
et al., 2003), recommends an extensive use of statins, folic acid, B vitamins and 
hydroxychloroquine. 
3.3 Management of valve abnormalities 
Valve abnormalities in the form of vegetation and/or thickening similar to Libman-Sacks 
endocarditis, are the most common cardiac manifestation in APS (~ 35%). They are defined 
by the “coexistence of aPLs along with echocardiografic detection of lesions and/or 
regurgitation and/or stenosis of mitral and/or aortic valve or any combination of the 
above” (Miyakis et al., 2006). Although anticoagulation do not cure valve vegetations, 
treatment is recommended in order to prevent valve thrombosis and arterial 
thromboembolism. Valve vegetations are in fact associated with cerebral involvement, 
especially stroke but also epilepsy, migraine and cognitive dysfunction. Use of aspirin is 
appropriate in asymptomatic patients. Administration of corticosteroids is controversial, 
and some authors advise against their use, considering them ineffective or even capable of 
further compromising valve functionality. It has been suggested that aPLs cross-react with 
antigens on the surface of valves, roughly as in the case of rheumatic fever, leading to 
inflammation and thrombosis of valve leaflets. On the hypothesis that  inflammation is the 
initial event of valve damage, Petri recommends a short course of corticosteroids with 
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follow-up 2D cardiac echocardiograms to determine the rate of corticosteroid taper (Petri, 
2004). A small minority of APS patients (~ 5%) develop a valve disease that is severe enough 
to require surgical therapy including commisurotomy, annuloplasty and biological or 
mechanical valve replacement. Mechanical valve replacement may be a better option 
compared to bioprothesis due to the fact that patients are already anticoagulated and that 
mechanical valves last longer. 
3.4 Management of intracardiac thrombosis 
Intracardiac thrombi are a rare complication of APS. They may occur in all cardiac chambers 
but mainly in the right heart and are a dangerous source of systemic embolization. 
Erdogan’s series showed mural thrombi in 13% of cases in the absence of local conditions 
favoring blood stasis, and thrombi were treated with aggressive anticoagulation and 
surgical excision (Erdogan et al., 2005). There are no studies comparing medical, surgical or 
mixed treatments. The Committee Consensus  recommends to start warfarin therapy as 
soon as a thrombus is detected, and to consult the cardiac surgeon when appropriate 
(Miyakis et al., 2006). 
3.5 Management of anticoagulation in cardiopulmonary bypass surgery 
APS patients undergoing cardiac surgery show very high perioperative morbility and 
mortality rates due to thromboembolic events, especially cerebrovascular ones, to 
bleeding, acute biventricular failure and multiple organ failure caused by catastrophic 
APS triggered by surgery. Colli showed a 50% morbility rate and a 22% mortality rate in 
nine patients who underwent heart valve surgery (Colli et al., 2010). Safe and effective 
anticoagulation during cardiopulmonary bypass (CPB) surgery depends largely on 
adequate monitoring of coagulation parameters, but that is a challenging task because of 
the aPLs interference with in vitro hemostasis tests. Furthermore, the contact of blood 
with extracorporeal surfaces during CPB stimulates the coagulation cascade. APLs 
prevent the binding of coagulation proteins to the phospholipid surfaces, resulting in 
prolonged activated partial thromboplastin time (aPTT) and/or activated clotting time 
(ACT). In these circumstances anti-Xa factor monitoring is the gold standard laboratory 
test to be used. When treating venous thromboembolism, the target range of anti-Xa 
activity is 0.6 ± 1.0 u/ml ± 1. Anti- Xa levels of 1.5 ± 2.0 u/ml ± 1 are considered 
therapeutic for CPB. However, it is difficult to tune the implementation of anti- Xa assays 
to CPB, due to the time constraints of the latter (Koniari et al., 2010). Some authors have 
therefore suggested to double the ACT baseline value, on an empirical basis, to more than 
999 seconds, while others (East et al., 2000)  proposed a  preoperative set-up of heparin-
celite/ACT titration curves in order to assess the effect of aPL antibodies on ACT 
monitoring. There is no consensus in literature on the best way to ensure adequate 
intraoperative anticoagulation but heparin is routinely administered for its safety profile 
and the broader clinical experience. In the six case report Weiss refers to, unfractionated 
heparin was administered at doses ranging from 357U/Kg to 775U/Kg, without any 
intraoperative complications due to ineffective anticoagulation (Weiss et al., 2008). One 
patient suffered from postoperative bleeding, and in all cases target ACT was higher than 
550 seconds. Other therapeutic strategies, such as the one based on the use of bivalirudin, 
have been performed on APS patients with heparin-induced thrombocytopenia. 
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Bivalirudin is a direct thrombin inhibitor that produces an effective attenuation of 
thrombus formation due to its particular action. In fact bivaluridin not only inhibits the 
active site of the thrombin, but it also recognizes its fibrinogen-binding site, preventing 
the activation of both the fluid-phase thrombin and the fibrin-bound thrombin. In the case 
of bleeding due to excessive anticoagulation, protamine sulfate should be continuously 
administered in small intravenous doses, e.g. 50 mg/h (Gorki et al., 2008), until the 
bleeding is reduced. Antifibrinolytic drugs, aprotinin or plasmin inhibitors, which are 
commonly used to stop the bleeding, are not usually given because of the potential risk of 
postoperative thrombosis. In two cases, however, epsilon-aminocaproic acid was 
administered without incurring in any subsequent complication. In conclusion, 
antithrombotic perioperative strategies, which must be agreed upon with the 
hematologist, should be identified in all APS patients undergoing cardiac surgery. 
3.6 Management of myocardial dysfunctions 
It is debated whether APS patients may experience a systolic or diastolic dysfunction 
unrelated to hypertension, valve heart disease or CAD. Isolated autoptic studies in subjects 
who died of heart failure, showed diffuse cardiomiopathy with microthrombosis of small 
intramyocardial arterioles with surrounding microinfarctions without vasculitis, suggesting 
a direct thrombotic effect of aPLs. Myocardial thrombothic microangiopathy has been found 
in catastrophic APS patients who suffered from MI with a normal  angiographic profile of 
coronary arteries. Echocardiographic studies have shown the presence of primitive diastolic 
dysfunction despite the absence of systolic dysfunction or other cardiac disease. In a cross-
sectional study (Tektonidou et al., 2001) the echocardiographic parameters reflecting right 
ventricular dysfunction (prolonged deceleration time, isovolumetric relaxation time, E/A 
ratio-parameters) were associated with high titers of aCLs. As in other cardiac diseases, the 
diastolic dysfunction may in some cases anticipate overt left ventricular failure. We do not 
know what treatment is effective in preventing myocardial dysfunctions and therefore the 
treatment administered should be the one recommended by the systolic and diastolic heart 
failure guidelines. 
3.7 Management of Pulmonary Hypertension 
See 4.3 Pulmonary Hypertension 
4. Management of lung diseases 
4.1 Introduction 
A wide variety of pulmonary manifestations are found in APS patients. The most frequent 
ones are Pulmonary embolism (PE) and Pulmonary hypertension (PH), while the less 
common ones include Acute respiratory distress syndrome (ARDS) and Diffuse alveolar 
hemorrhage (DAH). 
4.2 Acute pulmonary embolism. Treatment 
Acute pulmonary embolism is the most frequent pulmonary complication (40%) and in 
about half the cases is preceded by deep venous thrombosis (DVT). Its treatment does not 
differ from the one adopted on non-APS patients: acute anticoagulation with unfractionated 
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or low molecular weight heparins, followed by long-term oral warfarin. In the event of 
adverse reactions or other contraindications to heparin, the use of direct thrombin inhibitors 
in the acute phase (e.g. intravenous hirudin and its derivative bivaluridin) or Xa factor 
inhibitors (fondaparinux) is recommended (Tapson & Humbert, 2007). In patients with 
recurrent PE due to persistent DVT of the legs, the placement of inferior vena cava filters 
may be performed. Thrombolytic therapy, as in all patients with acute PE, is indicated in the 
case of hemodynamic instability associated with acute right ventricular failure. As 
previously discussed when debating the intensity of anticoagulation, it seems reasonable to 
recommend an international normalized ratio (INR) between 2.5 and 3.5. 
4.3 Pulmonary Hypertension 
4.3.1 Preliminary remarks 
Pulmonary Hypertension (PH) is a serious condition with significant morbidity and 
mortality rates, which has a frequency of 3.5% in primary APS and of 1.8% in APS with SLE. 
PH in APS develops as a result of: A - acute pulmonary embolism, B - mitral/aortic 
valvulopathy in Libman-Sacks endocarditis, and C - in the absence of identifiable lung or 
cardiac disease (Idiophatic pulmonary hypertension). A - Chronic thromboembolic 
pulmonary hypertension (CTEPH) develops in about 3% of subjects who experienced an 
episode of acute PE with relation to incomplete resolution of acute clotting, leading to an 
endothelial damage triggering a series of remodeling events with in situ development of 
microthrombi (Hoeper et al., 2006). B - In the Libman-Sacks endocarditis, non-bacterial 
vegetations cause valvular regurgitation, high left heart filling pressures that lead over time 
to passive pulmonary venous hypertension. C - The association of aPLs with Idiophatic  
pulmonary hypertension (IPAH) is mentioned in studies regarding small series of patients: 
in 24 patients, mainly SLE ones, aPLs were found in 68% of cases (Asherson et al., 1990). The 
role of aPLs in the IPAH pathogenesis is unknown but they may induce the production of 
endothelin-1 (ET-1), a powerful vasoconstrictor, in some patients. 
4.3.2 Pulmonary Hypertension. Treatment 
Chronic anticoagulation, necessary to prevent the formation of new thromboemboli, is 
paramount in PH, but the treatment of choice remains the pulmonary 
thromboendoarterioctomy (PTE) introduced by Jamieson (Jamieson et al., 2003). The 
surgical procedure requires a very complex technique performed in cardiopulmonary 
bypass with intermittent circulatory arrest that allows the surgeon the full view of the 
thromboembolic material and its dissection. PTE should be performed early in the course 
of the illness when pulmonary vascular resistance, measured via right heart 
cathetherization, is still not irreversibly high, as mortality is related to the degree of 
preoperative vascular resistance. If a high resistance persists after surgery, that is a sign of 
strongly negative outcome. For this reason some authors suggest to perform PTE only if a 
significant improvement in pulmonary vascular resistance (> 50%) is expected after 
surgery (Dartevelle et al., 2004). In patients who are ineligible for surgery, the literature 
produced between 1990 and 2000 reported variable success rates with relation to 
vasodilator therapy with calcium channel blockers or with long-term infusion of 
epoprostenol (prostacyclin). From a general point of view, we have drugs for the 
treatment of pulmonary arterial hypertension (PAH), approved by the United States Food 
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and Drug Administration (FDA), that antagonize the three pathogenic mechanisms of 
PAH: 1. endothelin receptor antagonists (relative excess of ET-1), 2. phosphodiesterase-5 
inhibitors and 3. prostacyclin analogues (relative deficit of nitric oxide and 
prostaglandins). Bosentan, a non selective oral endothelin receptor antagonist, is used to 
improve exercising capacity in IPAP and in PH depending on either scleroderma or 
congenital systemic-to-pulmonary shunts of the Eisenmenger's syndrome, but its 
application in other forms of secondary pulmonary hypertension is uncertain. Pulmonary 
venous hypertension caused by valve abnormalities in Libman-Sacks endocarditis, 
requires the implementation of the usual measures aimed at reducing pulmonary 
congestion, first of all the administration of diuretics.Valve replacement may be necessary 
if left ventricular dysfunction becomes severe. Anticoagulation is recommended to 
prevent valve thrombosis and subsequent systemic embolic phenomena, but the treatment 
does not fix valvular lesions (See 3.3 - Management of valve abnormalities). 
4.4 Acute respiratory distress syndrome (ARDS). Treatment 
ARDS is a form of non-cardiogenic pulmonary edema that occurs in the setting of normal 
atrial and ventricular filling pressures. It is defined by the presence of bilateral pulmonary 
infiltrates with a partial pressure arterial oxygen (PaO2) to fraction of inspired oxygen 
(FiO2) ratio below 200 , and it is most frequently reported in catastrophic APS. In the early 
stages of ARDS, the alveolar capillary membrane permeability is increased, causing the 
passage of red cells and neutrophils into the alveoli. The migration of immunoglobulins and 
aPLs into the alveoli has also been demonstrated, suggesting the key role of aPLs in driving 
the ARDS process. On the other hand, it is possible to assume that the ‘cytokine storm’ 
found in CAPS is the main event increasing capillary permeability with neutrophils 
migration. The management of ARDS patients consists, apart  from anticoagulation, of high 
doses of steroids and, occasionally, of pulses of cyclophosphamide and plasmapheresis 
(Stojanovic, 2006). 
4.5 Diffuse alveolar hemorrhage. Treatment 
Diffuse alveolar hemorrhage (DAH) shows widespread alveolar infiltrates determining 
dyspnea, cough, fever, hypoxemic respiratory failure with hemoptysis found in 70 % of 
cases. The histological lesion at the basis of DAH is pulmonary capillaritis, in which the 
migration of neutrophils into the interstitium causes necrosis and damage to capillary 
integrity, with intra-alveolar red cell extravasation. Such migration may be caused either by 
aPLs, through the up-regulation of endothelial cell adhesion molecules, or by the C5a 
complement fraction that activates neutrophils. Treatment is the same as in ARDS,with 
corticosteroid and cyclophosphamide immunosuppression representing an important 
therapeutic tool. It starts with the administration of high doses of corticosteroids (IV 
methylprednisolon 1g/d for 3-5 days) and cyclophosphamide pulse therapy is used if 
recurrence occurs after the cessation of steroids. Almost all DAH patients already treated 
with corticosteroids improve after the addition of cyclophosphamide (Deane & West, 2005). 
In refractory cases, IV immunoglobulins and plasma exchange may be used. In the case of 
hemoptysis, it may be necessary to suspend anticoagulation and resume treatment as soon 
as lung conditions improve. 
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5. Management of kidney diseases in APS 
5.1 Introduction 
Renal manifestations in APS depend on the involvement of intrarenal small vessels, causing 
APS nephropathy (APSN), and of large extrarenal vessels. 
5.1.1 APS nephropathy 
APS nephropathy is a well defined clinicopathological entity characterized by a vasoocclusive 
disorder of the kidney microcirculation. It includes acute lesions in form of Thrombotic 
Microangiopathy (TMA) with mesangiolysis and/or double contours of the glomerular wall, 
variously associated with chronic lesions (fibrous intimal hyperplasia, focal cortical atrophy, 
arteriolosclerosis, tubular thyroidization) (Nochy et al.,1999). The prevalence of 
microangiopathic thrombotic lesions causes acute kidney failure often associated with 
malignant hypertension and nephrotic or sub-nephrotic proteinuria. Chronic lesions are 
associated with moderate hypertension, chronic kidney failure and mild proteinuria. Fibrous 
Intimal Hyperplasia (FIH) shows intimal thickening by myofibroblastic cells leading over time 
to arteriolar occlusion due to fibrous projections and organized thrombi. Focal Cortical 
Atrophy (FCA) is characterized by focal areas of fibrosis and retraction of the subcapsular 
cortex on ischemic basis. The described lesions are found in primary APS, in secondary APS 
with SLE nephritis, with TMA being especially observed in catastrophic APS. In SLE patients 
with aPLs, APSN occurs in a very high percentage (39.5%) (Tektonidou et al., 2004) while it is 
present  in just 4.3% of SLE patients without aPLs. APSN in addition to SLE represents an 
additional risk factor for renal morbidity, hypertension and interstitial fibrosis, the last two 
being well known prognostic indicators of kidney function. During catastrophic APS, kidneys 
are the organs most frequently involved (71%) (Cervera et al., 2009), resulting in acute renal 
failure, severe hypertension, proteinuria and hematuria. 
5.1.2 Involvement of extrarenal vessels 
Hypertension is commonly observed in both primary and secondary APS, and is  frequently 
associated with livedo reticularis. Uncontrolled hypertension can be caused by renal artery 
stenosis (RAS) or, less commonly, by renal infarctions (Alchi et al., 2010). RAS shows two 
angiographic patterns: generally smooth, non-critical stenosis in the mid-portion of the renal 
artery and, rarely, more proximal atherosclerotic-like lesions. The nature of RAS in APS 
remains unclear, but the good response to anticoagulation with recovery of renal function 
and normalization of blood pressure, suggests the existence of a thrombotic  basis (Godfrey 
et al., 2000). Finally, both primary APS and aPL-positive patients with SLE nephritis, 
especially those who are LA positive, are prone to develop thrombosis of the renal veins and 
inferior vena cava, associated with nephrotic range proteinuria. 
5.2 Treatment 
The management of renal manifestations of APS depends mainly on the identification of 
specific complications, either intra- or extrarenal, and it is similar to the general treatment of 
APS. The basic principles of the treatment are as follows: A - general measures to reduce 
renal damage progression, B - treatment of APS nephropaty, C -  treatment of extrarenal 
vascular occlusions/stenosis, D - treatment of kidney failure in CAPS. A - In an attempt to 
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slow down the decrease of the glomerular filtration rate, we should identify and address the 
factors that contribute to kidney damage, with particular relation to hypertension. 
Symptomatic treatment is based on the inhibition of the renin-angiotensin system, whose 
role in the genesis of renal injury is largely acknowledged. ACE inhibitors and AT1 receptor 
antagonists are the elective therapeutic remedies. The blocking effect of the renin-
angiotensin system results in a specific renoprotective action (Fogo, 2001), in a containment 
of proteinuria and in a better control of hypertension. The mean arterial pressure should be 
kept within the 90 mm/Hg value. Other forms of renal protection  include general measures 
of containment of the vascular risk and,where indicated, a low dietary protein intake, 
usually with serum creatinine > 2- 2,5 mg/dl. B - Treatment of APS nephropathy is based on 
anticoagulation with heparins and warfarin. Although there are no evaluation studies on 
anticoagulant therapy in aPL-associated nephropathy, anticoagulation with warfarin should 
be lifelong, because the risk of recurrent thrombotic events exceeds the risk of bleeding. 
Immunosuppressive agents are not used in primary APSN because they do not prevent 
thrombosis, even though a few reports showed beneficial effects, perhaps on the basis of a 
decrease in the aPL-induced inflammatory response. For instance, cyclophosphamide (500 
mg/m2 IV monthly for twelve months) or azathioprine (2.0 mg/kg/day) and steroids were 
administered by Korkmaz with some effectiveness in patients with moderate renal 
insufficiency (creatinine: 1.0-2.7 mg/dl) and variable proteinuria (0.6-10.1 g/24 h), in 
combination with warfarin (to ensure an INR > 2.5) (Korkmaz et al., 2003). The 
immunosuppressive treatment is mandatory in patients with APS nephropaty associated 
with SLE nephritis, where warfarin is administered with corticosteroids and cytotoxics, 
usually cyclophosphamide and azathioprine. Mycophenolate mofetil has recently proved 
more effective than cyclophosphamide in inducing remission of severe lupus nephritis with 
fewer side effects, and it might represent a viable alternative to azathioprine in maintenance 
therapy (Zhu et al., 2007). C – Occlusive and/or stenotic complications regarding extrarenal 
vessels are treated with unfractionated or low molecular weight heparins followed by oral 
anticoagulation with warfarin. With relation to RAS, anticoagulant therapy may play a role 
in stabilizing or improving stenosis and in preventing restenosis after angioplasty. Some 
reports showed that anticoagulation with INR >3 may reverse arterial stenosis and achieve 
subsequent clinical improvement (Sangle et al., 2005; Ben-Ami et al., 2006). D - First-line 
APSN therapy associated with catastrophic APS is based on a combination of corticosteroids 
plus IV immunoglobulins and/or plasma exchange (see 8.- Management of Catastrophic 
APS). We think that IV immunoglobulin or plasma exchange may also play a role in acute 
forms of APSN supported by TMA unresponsive to anticoagulation, and that extracorporeal 
immune-absorption procedures, that selectively remove IgG molecules, may represent a 
viable alternative to traditional apheretic techniques. 
6. Management of thrombocytopenia in APS 
6.1 Introduction 
Thrombocytopenia, defined by a platelet (PLT) count of less than 100-150 x 109/L, is one of 
the main features of APS, found in ~ 25% of PAPS patients and in ~ 40% of cases of APS 
with SLE. Furthermore, primary immune thrombocytopenia (PIT) and APS have in common 
aPL autoantibodies, suggesting a similar pathophisiology. Liebman’s review reported six 
studies - published between 1994 and 2006 – that showed a very frequent (~ 50%) detection  
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of aPLs in PIT (Liebman, 2007). Those papers showed no correlation between aPLs titre and 
severity of thrombocytopenia (PLT count <50 x109/L). Two of them established a relation 
between aPLs and rates of thrombotic events, albeit with discordant results. In Stasi’s study 
no thrombotic event was revealed at median follow-up of 31 months (Stasi et al.,1994), while 
Diz-Kucukkaya found that aPLs positivity, specifically LA positivity, is an important 
thrombotic risk factor (Diz-Kucukkaya et al., 2001). In fact 60% of aPL-positive patients, but 
none of the aPL-negative, developed thrombotic events at the five-year follow-up. The 
mechanism of thrombocytopenia in APS is unknown and most authors state it is immune-
mediated and not due to a consumptive process. 
6.2 Treatment 
Thrombocytopenia associated with APS is usually moderate (> 50 x109/L), it shows no 
clinical manifestations and rarely requires interventions. Treatment is indicated when 
thrombocytopenia is marked (<30 x109/L) and symptomatic with bleeding. Therapeutic 
options include steroids, intravenous immunoglobulins (IVIG), immunosuppressive agents 
(azathioprine, cyclophosphamide) (Lim, 2009). The employment of newer agents such as 
rituximab, and exceptionally the practice of splenectomy, should be considered in case of 
failure of conventional therapies. In the absence of clinical trials or guidelines, Galli 
suggested that treatment regimes of APS thrombocytopenia should be similar to those of 
PIT, due to their shared features and pathophisiology (Galli et al., 1996) . We extrapolated 
the following therapeutic patterns, with the relevant drug dosages, from the recent 
International Consensus Report on the Investigation and Management of Primary Immune 
Thrombocytopenia (Provan et al., 2010). First-line therapy: 1 - Glucorticoids are the standard 
initial treatment. Prednisone is usually administered in doses of 0.5-2mg/kg/d. 
Administration of dexamethasone 40 mg/day (equivalent to 400 mg of prednisone a day) 
for 4 days every 2-4 wk for 1-4 cycles, produces sustained response on the PLT count. 
Parenteral administration of high-dose methylprednisolon (30 mg /kg/d for 7 d) followed 
by oral steroids, is also effective . 2 - IV immunoglobulins: IVIG treatment shows a quicker 
response in PIT compared to corticosteroids. The standard regimen includes the infusion of 
0.4 g/kg/d for 4-5 days, but we are more likely to obtain a PLT increase using high doses of 
1g/Kg/d for 1 or 2 days. Rare but dangerous toxicities include kidney failure and 
thrombosis. Second-line treatment options: 1 - immunosuppressive agents are used in order to 
achieve an increase of the PLT count considered hemostatic for the individual patient. 
Azathioprine is administered at doses of 1-2 mg/kg/d (maximum 150 mg/d), and it shows 
fewer side effects compared to other immunosuppressants: weakness, sweating, increased 
transaminases, neutropenia with infection, pancreatitis. Cyclophosphamide may be 
administered either orally (1-2 mg/kg/d) or IV (0.3-1g/Kg for 1-3 doses every 2-4 weeks). 
Toxicity is mild to moderate and it includes neutropenia, nausea and vomiting, deep leg 
venous thrombosis. 2 – Rituximab is usually given at doses of 375 mg/m2 every week for 4 
weeks. In PIT, Rituximab causes a PLT count response in approximately 64% of patients, 
with a response duration ranging from five to 48 months. The efficacy of rituximab in the 
treatment of APS patients with thrombocytopenia is still to be determined and only a few 
studies can be found in literature (Ames et al., 2007; Trappe et al., 2006; Ahn et al., 2005). The 
most common side effects are infusion-related, such as fever, chills, headache, rash, 
bronchospasm and hypotension, mostly occurring during the first infusion. After the 
administration of rituximab, peripheral B cell levels show a dramatic decrease, returning to 
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near baseline from 6 to 12 months after completion of therapy. Despite such B-cell depletion, 
a decrease in serum immunoglobulin  levels is only found in a minority of patients. 
Rituximab should not be used in patients with active B hepatitis, because of the risk of 
hepatitis activation. 3 – Splenectomy is a viable treatment option in thrombocytopenic 
patients, as approximately 20% of them show a very low PLT count, despite medical 
treatment and pheresis. Eleven out of fifty-five APS patients with thrombocytopenia 
required a splenectomy in a retrospective study (Galindo et al., 1999), that reported a high 
rate of successful long term response. In view of the potential risk of post-splenectomy 
arterial thrombosis, intervention should be reserved to severe and symptomatic forms of 
thrombocytopenia, unresponsive to more conventional treatment. Finally, literature cites 
isolated cases of thrombocytopenia in APS with good therapeutic response to danazol, 
aspirin, dapsone, chloroquine. 
6.3 Treatment of bleeding complications 
Bleeding is considerably less frequent than thrombosis, as shown by the Italian Registry of 
Antiphospholipid Antibodies, which takes into account 319 patients: only 4 out of 80 of 
thrombocytopenic subjects suffered major bleeding events. Finazzi, revising the same 
Registry, found 32% of thrombotic events, but no bleeding, in 44 patients with a PLT count 
between 100-150 x109/L. (Finazzi, 1997). In the  32 patients with a PLT count < 50 x 109/L, 
bleeding was observed in 6%, and thrombosis in 9% of cases, indicating the possibility of 
thrombosis in spite of severe thrombocytopenia. In accordance with Lim’s review, we report 
the following practical recommendations regarding the treatment of active hemorrhages 
(Lim, 2009). Bleeding occurring in the central nervous, gastrointestinal or genitourinary 
system often requires a rapid increase of the PLT count. In some cases, it is sufficient to 
switch from the steroid to the immunoglobulin therapy, but it seems more appropriate to 
adopt a combination treatment with corticosteroids and IVIG. Platelet transfusions, leading 
to a post-transfusional PLT increase of about 20 x109/L, may be associated. Antifibrinolytic 
agents, such as oral or IV tranexamic acid (1 g, three times a day) and episilon-aminocaproic 
acid (1-4 g every 4-6 hours) may be useful in preventing recurrent bleeding. On the other 
hand, if bleeding is due to the anticoagulant treatment, therapy should be temporarily 
discontinued administering the relevant antidotes (protamine sulfate for heparin, vitamin K 
for warfarin), and practising the transfusional support (fresh plasma for heparin and 
warfarin, prothrombin concentrated complexes for warfarin). In patients with severe 
thrombocytopenia and high thrombotic risk, the PLT count should be brought to at least 30-
50 x109/L, for anticoagulation to be adequately performed. It does not seem useful to reduce 
the intensity of anticoagulation in those cases, as we infer from data regarding secondary 
prevention of deep vein thrombosis that low doses of warfarin are not protective. 
7. Management of dermatological diseases in APS 
7.1 Introduction 
The skin appears to be an important target organ for aPLs and 40% of the patients may present 
cutaneous features as a major complaint. Skin lesions may be sorted according to their 
seriousness in ‘major’ (widespread cutaneous necrosis and/or digital gangrene) and ‘minor’ 
(e.g. livedo reticularis, superficial thrombophlebitis, pseudo-vasculitis lesions, circumscribed 
ulcerations, subungual splinter hemorrhages). Major ones are caused by non inflammatory 
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thrombosis of small arteries of the dermis and subcutaneous fat. The most frequent (17.5% to 
40%) and typical skin manifestation is livedo in both its reticularis and racemosa versions, 
characterized by a purplish reticular or mottled skin pattern consisting of regular unbroken 
circles (livedo reticularis) or irregular circles (livedo racemosa), that is irreversible even after 
rewarming. Livedo racemosa has a more generalized location, being widespread all over the 
trunk, limbs and buttocks. The distinctive skin color of livedo is related to the reduced blood 
flow and the oxygen tension caused by vasoconstriction. Some authors state that livedo 
racemosa is a predictor of systemic thrombotic events, as there is evidence of a strong 
association between the former and cerebrovascular/ocular ischemic events, arterial 
thrombosis, migraine, epilepsy and renal artery stenosis (Toubi et al., 2005). The association of 
livedo with Sneddon's syndrome, typically affecting women before or during their middle age, 
is debated.This syndrome shows widespread livedo that precedes the onset of stroke by 
several years, and many authors found that 40%-50% of the patients affected are aPL-positive 
(Frances et al., 1999). The relationship between livedo and arterial thrombosis suggests a 
possible common role played by endothelial cells. In fact, many aPLs interact with the 
phospholipid-protein complexes on the surface of endothelial cells, therefore leading to the 
production of procoagulant substances such as tissue factor (TF), plasminogen activator 
inhibitor-1 and endothelin-1. This interaction between aPLs and endothelial cells may cause 
the vasoconstriction typical of livedo racemosa (Amengual et al., 1999). 
7.2 Treatment 
The treatment of patients with cutaneous manifestations should take into account the kind 
of skin lesion and the overall clinical situation. In the absence of RCTs regarding 
prophylaxis and therapy of dermatological lesions, treatment remains empirical. Digital 
gangrene and skin necrosis are the major thrombotic events requiring full anticoagulation 
with heparin (Rossini et al., 2002). Should lesions persist despite anticoagulation, some 
reports suggest alternative treatments (iloprost, tissue plasminogen activator, 
gammaglobulins, corticosteroids, plasma exchange and immunosuppressive therapy) 
(Frances et al., 1989; Srinivasan et al., 2001; Zahavi et al., 1993). Major cutaneous lesions may 
appear particularly serious in the context of multiorgan thrombotic occlusion during 
catastrophic APS in which combined treatments are required ( see 8.- Management of 
Catastrophic APS). Frances recommends long-term anticoagulation with INR targeted to 2.5 
for the prophylaxis of severe skin lesions (Frances, 2010). In patients who have ‘minor’ 
cutaneous manifestations with no other systemic  features, e.g. circumscribed  ulcers or 
pseudovasculitis lesions, the administration of low doses (75 mg/d) of aspirin may be 
useful, although anticoagulant therapy must be adopted if lesions persist or worsen 
(Asherson et al., 2006). In any case, removal of the necrotic tissue and local antiseptic 
therapy are paramount for the reduction of the infective risk. Livedo racemosa resists to 
anticoagulant or antiplatelet  therapies, as it appears and extends in spite of them. In the 
European APS cohort (Cervera et al., 2002), where most patients were anticoagulated, livedo 
appeared in 26 cases during the five-year follow-up. Livedo is less evident in tanned areas, 
but it is known that exposure to sunlight is not recommended for SLE patients with APS. In 
view of the thrombotic risk in aPL-positive patients with livedo, it is important to reduce or 
remove other provoking factors, therefore men are advised to stop smoking and women not 
to use contraceptive pills containing estrogens. For the same reason, those patients should 
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be properly screened in order to detect silent cerebral ischemia and/or kidney illnesses, and 
warfarin therapy should be adopted if needed. Even though low doses of aspirin are 
commonly prescribed to patients with livedo and no systemic features, its effectiveness in 
the prevention of strokes remains doubtful. 
8. Management of catastrophic APS 
8.1 Introduction 
In 1992 Asherson described a potentially life-threatening variant of APS called catastrophic 
APS (CAPS), and subsequently named Asherson's syndrome (Asherson, 1992). It is 
characterized by multiple organ failure due to thrombothic microangiopathy (TMA) 
involving several organs, either simultaneously or in rapid sequence: brain, heart, kidneys, 
lungs, gastrointestinal tract. In 35% of cases it is possible to identify a triggering factor, 
which is mainly an infection or sepsis originating from the respiratory, urinary, 
gastrointestinal tracts.A pathogenic link between infections and CAPS has been 
acknowledged and its rationale is based on the theory of molecular mimicry, according to 
which ǃ2GPI peptides share the aminoacid sequence and conformational structure with 
common bacteria and viruses. As common microbial structures represent the natural  ligand 
for toll-like receptors (TLRs), it has been argued that ß2GPI might interact with TLRs and 
that anti-ß2GPI antibodies recognizing the molecule might cross-link it together with TLRs 
(Espinosa et al., 2007). Ultimately, TLRs intracellular signaling pathway leads to a 
proinflammatory and prothrombotic phenotype of endothelial cells, respectively through 
the production of proinflammatory cytokines and adhesions molecules, and the up 
regulation of the tissue factor. Other triggering factors of CAPS are the withdrawal or the 
administration of low doses of anticoagulants, invasive or surgical procedures, cancer, lupus 
flares, obstetric complications. 
8.2 Treatment 
CAPS appears in less than 1% of APS patients and carries a high mortality rate. Although there 
are no RCTs for this rare syndrome, the CAPS International Registry, accessible via the Web, 
provides us with important clinical, prognostic and therapeutic data. We can see that the 
CAPS  mortality rate went to 33% between 2001 and 2005, down from 50% in the years before 
2000 (Bucciarelli et al., 2006), and that may be due to the early treatment of triggering factors 
and even more to the improvement of first-line therapy, which should always include 
anticoagulation, corticosteroids and plasma exchange. This is in accordance with the 
International Consensus on CAPS management guidelines (Asherson et al., 2003) that 
recommends: effective anticoagulation with IV heparin, plus high doses of steroids, plus IV 
Immunoglobulins (IVIG) and/or plasma exchange (PE). The following are some 
considerations on the use of A. corticosteroids, B. immunoglobulins and C. plasma exchange 
with relation to this syndrome: A. Corticosteroids interact with the cytoplasmic receptor, and 
the resulting steroid receptor complex neutralizes Nuclear Factor-kB (NF-kB), which in turn 
activates transcription genes for the synthesis of pro-inflammatory molecules (TNF-, 
interleukins-1 and 2, cyclooxygenase-2 and intercellular adhesion molecules (ICAM). 
Moreover, corticosteroids partly neutralize activator protein-1, triggering the transcription of 
several genes involved in the synthesis of pro-inflammatory proteins. There is evidence of NF-
kB playing an important role in states, such as sepsis and ARDS, frequently associated with 
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CAPS. Consequently, the inhibition of NF-kB and the down regulation of the cytokines, both 
corticosteroid-induced, are beneficial in reducing host-derived tissue injury and organ 
dysfunctions when treating CAPS. B. IV immunoglobulins, that are immunomodulating 
agents, perform several activities. These include block of pathological autoantibodies, 
modulation of complement activation, clearance of pathological IgG and suppression of 
pathogenic cytokines. IVIG contain anti-idiotypic antibodies capable of recognizing and 
specifically suppressing different autoantibodies. That might explain both the short term 
neutralization of the aPLs pathogenic role and the long term decrease in the aPLs titre. (Vora 
and al., 2006). C. The effectiveness of plasma exchange therapy is widely acknowledged, 
although both the replacement fluid to be used (whether albumin solutions or fresh frozen 
plasma) and the timing and frequency of treatments, are still debated (Uthman et al., 2005). 
The guidelines recommend the use of fresh frozen plasma (FFP), especially in the presence of 
thrombotic microangiopathic hemolitic anemia (e.g. schistocytes). In fact thrombotic 
microangiopathies (TTP, HUS, HELLP syndrome) have in common with CAPS similar 
hematological manifestations (aPL positivity, thrombocytopenia, microangiopathic hemolitic 
anemia) and triggering factors (e.g. infections, drugs) (Asherson, 2007). Moreover such 
conditions, including HELLP syndrome at post-partum period, may require similar treatment 
with plasma exchange, using fresh frozen plasma instead of albumin reinfusion. 
(Szczepiorkowski et al., 2007). Although the exact mechanism of plasma exchange is still 
unknown, it has been demonstrated that PE is effective in removing  IgG-CL, anti-ǃ2GPI, 
cytokins, complement and TNF-ǂ. We propose the use of IV methylprednisolon at doses of 
1g/d for 3-5 consecutive days, followed by oral steroid at a dose equivalent to 1mg/Kg/d of 
prednisone; IV Immunoglobulins at 1g/Kg/d for two days ; plasma exchange with reinfusion 
of FFP not inferior to the volume of plasma, for at least 3-5 days. In the absence of clinical 
improvement, other therapies should be provided: cyclophosphamide in SLE flares, 
prostacyclin or fibrinolytics or defibrotide. In CAPS patients with severe thrombocytopenia 
resistant to other forms of treatment, the administration of rituximab may be useful, as the 
direct inhibition of B-lymphocytes contributes to the decrease of the aPLs titre and the 
subsequent platelet activation (Erre et al., 2008). Finally, the objectives to be aggressively 
pursued in the management of CAPS are essentially four: 1 - addressing the triggering factors 
(adoption of antibiotic therapy in the event of infection and surgical toilet of the infection 
sources), 2 - maintenance of effective anticoagulation, also when CAPS is associated with 
thrombocytopenia, 3 - suppression and/or removal of cytokine excess, 4 - adoption of 
intensive care measures when necessary. Such strategy plays an essential role in the survival of 
CAPS patients whose mortality, as shown by the CAPS registry data analysis regarding 112 
patients, is due to: neurologic involvement (mainly stroke) (27.2%); cardiac involvement 
(mainly cardiac failure) (19.8%); infections (mainly bacterial sepsis) (19.8%); multi organ failure 
(17.3%); pulmonary involvement  (mainly ARDS ) (9.8%); abdominal involvement, including 
liver failure and acute abdomen, in four patients (Espinosa et al., 2008). The presence of SLE is 
the only prognostic factor predicting a higher  mortality (59% vs 37.9%) regardless of clinical 
manifestations, number of organs involved, laboratory parameters and treatment adopted 
(Bayraktar et al., 2007).  
9. Conclusions 
In APS patients, the current therapeutic standard is oral anticoagulation aimed at 
preventing thrombotic events. Warfarin or coumarin inhibit the synthesis of vitamin K-
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dependent clotting factors (FII, FVII, FIX, FX) and of anticoagulant plasma proteins C and S. 
The INR target should be kept between 2 and 3 in case of first venous thrombotic event, 
while it should be higher than 3 in case of arterial thrombosis and/or recurrent venous 
thrombosis. In women with obstetric complications treatment is based on the use of aspirin 
and heparin. The treatment of choice for patients suffering from acute thromboembolic 
event is the administration of unfractionated heparin which, through the activation of ATIII, 
indirectly inhibits thrombin formation and inactivates Xa factor. Alternatively, we can use 
LMWH, whose binding to ATIII causes above all of all the inactivation of Xa factor, and then 
of thrombin to a lesser extent. LMWHs have a more predictable pharmacological effect and 
they induce thrombocytopenia less frequently, due respectively to their weaker binding 
with plasma proteins and with platelets. Anticoagulation may be ineffective or even 
contraindicated under certain clinical circumstances. In fact, some manifestations of APS, 
such as cardiac valvular disease, livedo reticularis and thrombocytopenia, are unresponsive 
to anticoagulation. Moreover, some patients experience thromboembolic events despite 
anticoagulation, while others do not tolerate full doses of warfarin because of its 
hemorrhagic side effects. Additional drugs have been introduced over the years in order to 
overcome such problems. Their therapeutic use has been found following experimental 
evidence, tested in vitro and/or on animal models, that revealed the pathogenic effects of 
aPL/ǃ2GPI complexes both on hemostatic reactions and on the activation of cellular 
elements (endothelials cells, monocytes , platelets), also clarifying the role of B cells in the 
aPLs synthesis. We think that clinical experiences based on thrombin-inhibitors, on 
hydrossycloroquine, statins and B-cell depletion therapy (e.g. rituximab) have been so far 
the most interesting ones and we can assume they will be consistently adopted in the 
management of APS. In particular dabigatran, a new direct thrombin-inhibitor, usually 
prescribed at a dose of 150 mg twice a day for the prophylaxis of post-operative venous 
thromboembolism, could represent a viable alternative to warfarin. Dabigatran is 
administered orally and does not require anticoagulation monitoring, although we need 
clinical studies validating its use in APS patients. Hydroxyicloroquine, which directly 
inhibits the binding of aPL/ǃ2GPI complexes to phospholipid surfaces, has the advantage of 
not causing bleeding, and therefore it is useful in patients showing hemorrhagic side effects 
caused by warfarin. Hydroxyicloroquine can also be used, in view of its antiplatelet effect, in 
those patients who have experienced thrombotic recurrences despite anticoagulation. It is 
usually administered at doses of 400-800 mg/d and, because of its potential retinal toxicity , 
ophtalmic examination is essential prior to therapy. Controlled studies regarding the 
effectiveness and safety of its use have not been produced yet. Statins are an additional tool 
in the APS treatment due to their anti-atherosclerotic and anti-inflammatory effect, only 
partially depending on the relevant cholesterol decrease. Experimental studies indicate that 
they may act by reducing the aPL-induced endothelial activation, by blocking NF-kB 
pathway and the subsequent synthesis  of adhesion molecules and IL-6, and by reversing 
the up-regulation of the tissue factor (Espinosa & Cervera; 2010). In addition, it has been 
shown that rosuvastatin is effective in reducing  venous thromboembolic events in non-APS 
patients but also in this case we do not have clinical data indicating that statins prevent the 
formation of thrombi in APS patients. The experience with rituximab is still limited 
although encouraging reports, mainly dealing with the recovery of thrombocytopenia, have 
recently been published. We are currently waiting for the results of the ongoing Pilot Study 
of Rituximab for the anticoagulation-resistant manifestations of APS (RITAPS). This open-
label trial will assess  safety and efficacy of rituximab in those manifestations of APS which 
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prove unresponsive to anticoagulation. In conclusion, despite promising results provided by 
the aforementioned treatments, we feel that well-designed randomized trials are still 
needed.  
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